معرفی
Mei Yee Koh is an Associate Professor in the Department of Pharmacology & Toxicology at the University of Utah College of Pharmacy. Her research focuses on tumor hypoxia, hypoxia-inducible factors (HIFs), and their roles in cancer progression and therapy resistance, particularly in kidney and liver cancers.
Education:
- BSc (Honors) in Biochemistry with Biotechnology from the University of Manchester
- PhD in Molecular Pharmacology from the University of Manchester
Research Interests
- Investigating the HIF switch mechanism in clear cell renal cell carcinoma (CCRCC) and its role in tumor aggressiveness
- Developing therapeutic strategies targeting HAF (Hypoxia-Associated Factor) and HIF-2α
- Studying inflammation-driven liver cancer (HCC) using SART1+/- mouse models
- Exploring the interplay between tumor hypoxia and immune cell suppression
Selected Research Trends:
- Targeting HIF signaling for cancer therapeutics
- Elucidating molecular pathways in hypoxia-induced ferroptosis
- Translational studies linking NASH to HCC
- Understanding the role of HAF in HIF isoform regulation
Labs & Teams: Leads the Genomic & Molecular Pharmacology of Cancer research group at the University of Utah, which developed SART1+/- mice for studying liver cancer progression and identified HAF as a critical mediator of the HIF switch in kidney cancer.
۰مقاله منتشرشده
